These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27086249)

  • 1. Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia.
    Leddy-Stacy MA; Rosenheck R
    Psychiatry Res; 2016 Apr; 238():304-309. PubMed ID: 27086249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Hermes ED; Sokoloff D; Stroup TS; Rosenheck RA
    J Clin Psychiatry; 2012 Apr; 73(4):526-32. PubMed ID: 22579152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures.
    Thwin SS; Hermes E; Lew R; Barnett P; Liang M; Valley D; Rosenheck R
    Psychiatry Res; 2013 Oct; 209(3):291-6. PubMed ID: 23473656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.
    Kozielska M; Pilla Reddy V; Johnson M; de Ridder F; Vermeulen A; Liu J; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):53-8. PubMed ID: 23434198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
    Chaichan W
    J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.
    Vernon MK; Revicki DA; Awad AG; Dirani R; Panish J; Canuso CM; Grinspan A; Mannix S; Kalali AH
    Schizophr Res; 2010 May; 118(1-3):271-8. PubMed ID: 20172695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
    Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
    Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
    J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.